Pituitary Stem Cells

Almeida, João Paulo; Sherman, Jonathan H.; Salvatori, Roberto; Quiñones‐Hinojosa, Alfredo

doi:10.1227/01.neu.0000373013.75994.cd

Cited by 13 publications

(3 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings support a potential role for adult pituitary stem cells in pituitary adenomas. Almeida et al suggested that the occurrence of plurihormonal and null cell-type adenomas (no distinguishable ultrastructural, immunohistochemical, or histologic characteristics of recognized adenohypophyseal cell types) supports the hypothesis that pituitary stem cells may be a potential source of pituitary adenomas ( De Ameida et al, 2010 ). Radian et al found that GH-and thyroid-stimulating hormone (TSH)-secreting cells share common progenitor cell expression.…”

Section: Potential Mechanismsmentioning

confidence: 99%

See 1 more Smart Citation

Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma

Cai,

Liu,

Zhao

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

Plurihormonal pituitary adenoma (PPA) is a type of pituitary tumor capable of producing two or more hormones and usually presents as an aggressive, large adenoma. As yet, its pathogenesis remains unclear. This is the first study to systematically summarize the underlying pathogenesis of PPA. The pathogenesis is related to plurihormonal primordial stem cells, co-transcription factors, hormone co-expression, differential gene expression, and cell transdifferentiation. We conducted a literature review of PPA and analyzed its clinical characteristics. We found that the average age of patients with PPA was approximately 40 years, and most showed only one clinical symptom. The most common manifestation was acromegaly. Currently, PPA is treated with surgical resection. However, recent studies suggest that immunotherapy may be a potentially effective treatment.

show abstract

Section: Potential Mechanismsmentioning

confidence: 99%

“…De Ameida et al, 2010).Radian et al found that GH-and thyroid-stimulating hormone (TSH)secreting cells share common progenitor cell expression. This suggests that TSH adenomas originate from pituitary stem cells that differentiate into GH, PRL, or TSH cells, which may play a role in the pathogenesis of TSH-secreting PPA…”

mentioning

confidence: 99%

Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma

Cai,

Liu,

Zhao

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…In addition, the histochemical analyses also indicate keratinization in CPs’ epithelial cells ( 25 - 27 ). The second theory postulates that CPs arise from pituitary progenitor or stem cells representing embryonal remnants of Rathke's pouch epithelium ( 28 - 33 ). Studies in mouse models have provided insights into the importance of stem cells in the tumorigenesis of craniopharyngiomas ( 34 ).…”

Section: Introductionmentioning

confidence: 99%

The molecular pathogenesis of craniopharyngiomas

Campanini

Almeida

Martins

et al. 2023

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Research from the last 20 years has provided important insights into the molecular pathogenesis of craniopharyngiomas (CPs). Besides the well-known clinical and histological differences between the subtypes of CPs, adamantinomatous (ACP) and papillary (PCP) craniopharyngiomas, other molecular differences have been identified, further elucidating pathways related to the origin and development of such tumors. The present minireview assesses current knowledge on embryogenesis and the genetic, epigenetic, transcriptomic, and signaling pathways involved in the ACP and PCP subtypes, revealing the similarities and differences in their profiles. ACP and PCP subtypes can be identified by the presence of mutations in CTNNB1 and BRAF genes, with prevalence around 60% and 90%, respectively. Therefore, β-catenin accumulates in the nucleus-cytoplasm of cell clusters in ACPs and, in PCPs, cell immunostaining with specific antibody against the V600E-mutated protein can be seen. Distinct patterns of DNA methylation further differentiate ACPs and PCPs. In addition, research on genetic and epigenetic changes and tumor microenvironment specificities have further clarified the development and progression of the disease. No relevant transcriptional differences in ACPs have emerged between children and adults. In conclusion, ACPs and PCPs present diverse genetic signatures and each subtype is associated with specific signaling pathways. A better understanding of the pathways related to the growth of such tumors is paramount for the development of novel targeted therapeutic agents.

show abstract

Tissue and Progenitor Cell Transplantation for the Management of Pituitary Disorders: From Harvey Cushing to the Next Frontier

Pendleton

Quiñones‐Hinojosa

2012

Human Fetal Tissue Transplantation

View full text Add to dashboard Cite

Pituitary Stem Cells

Cited by 13 publications

References 74 publications

Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma

Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma

The molecular pathogenesis of craniopharyngiomas

Tissue and Progenitor Cell Transplantation for the Management of Pituitary Disorders: From Harvey Cushing to the Next Frontier

Contact Info

Product

Resources

About